(1) Xiaoxia Liu#, Yanyu Zhang#, Wenhua Lu# Yi Han#, Jing Yang, Weiye Jiang, Xin You, Yao Luo, Shijun Wen, Yumin Hu and Peng Huang. Mitochondrial TXNRD3 confers drug resistance via redox-mediated mechanism and is a potential therapeutic target in vivo. Redox Biol. 2020 Jul 23;36:101652. (2) Shaoyong Peng, Yingjie Li, Meijin Huang, Guannan Tang,Yumo Xie, Daici Chen, Yumin Hu, Tiantian Yu, Jian Cai, Zixu Yuan, Huaiming Wang, Hui Wang, Yanxin Luo, Xiaoxia Liu*. Metabolomics reveals that CAF-derived lipids promote colorectal cancer peritoneal metastasis by enhancing membrane fluidity. INT J BIOL SCI.2022; 18(5): 1912-1932. (3) Shaoyong Peng#, Daici Chen#, Jian Cai#, Zixu Yuan, Binjie Huang, Yichen Li, Huaiming Wang, Qianxin Luo, Yingyi Kuang, Wenfeng Liang, Zhihang Liu, Qian Wang, Yanmei Cui, Hui Wang*, Xiaoxia Liu*. Enhancing cancer-associated fibroblasts fatty acid catabolism within a metabolically challenging tumor microenvironment drives colon cancer peritoneal metastasis. Mol Oncol. 2021 May;15(5):1391-1411. doi: 10.1002/1878-0261.12917. (4) Xiaoxia Liu#; Yanyu Zhang#; Yi Han#; Wenhua Lu; Jing Yang; Jingyu Tian; Peng Sun; Tiantian Yu; Yumin Hu; Hui Zhang*; Peng Huang*; Panpan Liu*; Overexpression of GLT1D1 induces immunosuppression through glycosylation of PD‐L1 and predicts poor prognosis in B-cell lymphoma. Molecular Oncology. 2020 May;14(5):1028-1044. (5) Liu, Xiaoxia#，Wang, Wei#，Samarsky, Dmitry，Liu, Li，Xu, Qian，Zhang, Wenqing，Zhu, Guangzu，Wu, Ping，Zuo, Xialin，Deng, Houliang，Zhang, Jingjing，Wu, Zhuomin，Chen, Xiaohui，Zhao, Lingfeng，Qiu, Zhiyong，Zhang, Zhongyi，Zeng, Qiyi，Yang, Wei，Zhang, Biliang(*)，Ji, Aimin(*) ，Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA. Nucleic Acids Research，2014，42(18)：11805-11817 (6) Lang Xie, Renli Huang, Hongyun Huang, Xiaoxia Liu*, Jinlong Yu*. Transcriptomics and Metabolomics identify drug resistance of dormant cell in colorectal Cancer. Frontiers in Pharmacology, 2022 Apr 8;13:879751. doi: 10.3389/fphar.2022.879751. (7) Li Wang, Qian Yang, Shaoyong Peng, Xiaoxia Liu*. The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells. Onco Targets Ther. 2019 Jul 8;12:5359-5373. doi: 10.2147/OTT.S212465. (8) Bohong Cen, Wenjie Liao, Zhen Wang, Linyuan Gao, Yuanyi Wei, Wen Huang, Shuai He, Xiaoxia Liu*, Xinghua Pan*, Aimin Ji*. Gelofusine Attenuates Tubulointerstitial Injury Induced by cRGD-Conjugated siRNA by Regulating the TLR3 Signaling Pathway. Mol Ther Nucleic Acids. 2018 Jun 1;11:300-311. (9) Xiaoxia Liu*, Li Wang, Weiye Jiang, Wenhua Lu, Jing Yang, Wenbiao Yang. B cell lymphoma with different metabolic characteristics show distinct sensitivities to metabolic inhibitors. J CANCER. 2018 Apr 12;9(9):1582-1591. (10) Chen, Shan(#)，Liu, Xiaoxia(#)，Gong, Wenfei，Yang, Huan，Luo, Daofei，Zuo, Xialin，Li, Wenshi，Wu, Ping，Liu, Li，Xu, Qian，Ji, Aimin(*)，Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts.，Oncology Reports，2013，29(1)：260-268 (11) Liu, Xiaoxia，Liu, Li，Xu, Qian，Wu, Ping，Zuo, Xialin，Ji, Aimin(*)，MicroRNA as a novel drug target for cancer therapy，Expert Opinion ON Biological Therapy，2012，12(5)：573-580
